Popular Trials
MEK Inhibitor
AZD6244 + Chemotherapy for Advanced Cancer
Recruiting1 awardPhase 1
Detroit, Michigan
This study is evaluating whether a combination of AZD6244 given orally twice a day with standard doses of selected chemotherapies will be safe and tolerable for cancer patients with advanced solid tumors. The highest tolerated dose of AZD6244 in combination with selected chemotherapies will be evaluated
Cancer Vaccine
Autogene Cevumeran + Atezolizumab for Cancer
Recruiting1 awardPhase 1
Scottsdale, Arizona
This trial tests a personalized cancer vaccine and an immune-boosting drug in cancer patients. The vaccine teaches the body to attack cancer, while the drug helps immune cells find and kill hidden cancer cells. This approach aims to induce strong anti-tumor responses by selecting suitable vaccines based on the patient's existing immune system.
Cancer Vaccine
NeoVax + Ipilimumab for Kidney Cancer
Recruiting1 awardPhase 1
Boston, Massachusetts
This trial is testing a new cancer vaccine for kidney cancer. The vaccine is personalized, meaning it is made from each patient's own tumor. The study will also test two other drugs, Poly-ICLC and Ipilimumab, in combination with the vaccine.
Popular Filters
Trials for Kidney Cell Carcinoma Patients
Cyclin-Dependent Kinase Inhibitor
NKT2152 + Palbociclib + Sasanlimab for Kidney Cancer
Recruiting1 awardPhase 2
Omaha, Nebraska
This trial is testing a new drug combination for patients with advanced kidney cancer who have already tried other treatments. The goal is to see if these drugs can work better together to stop cancer growth and help the immune system fight the disease.
HIF2α Inhibitor
Oral NKT2152 for Kidney Cancer
Recruiting1 awardPhase 1 & 2
Scottsdale, Arizona
This trial is testing NKT2152, a new oral drug, in adults with a specific type of kidney cancer who have no other treatment options. It aims to find the safest dose and see if the drug can effectively fight the cancer.
Immunotherapy
Entinostat + Aldesleukin for Kidney Cancer
Recruiting1 awardPhase 1 & 2
Los Angeles, California
This trial is testing a combination of drugs to treat metastatic kidney cancer. Entinostat may stop tumor cell growth, and aldesleukin may stimulate white blood cells to kill cancer cells. The goal is to see if this combination is more effective than current treatments.
Trials for Renal Cell Cancer Patients
Cyclin-Dependent Kinase Inhibitor
NKT2152 + Palbociclib + Sasanlimab for Kidney Cancer
Recruiting1 awardPhase 2
Omaha, Nebraska
This trial is testing a new drug combination for patients with advanced kidney cancer who have already tried other treatments. The goal is to see if these drugs can work better together to stop cancer growth and help the immune system fight the disease.
HIF2α Inhibitor
Oral NKT2152 for Kidney Cancer
Recruiting1 awardPhase 1 & 2
Scottsdale, Arizona
This trial is testing NKT2152, a new oral drug, in adults with a specific type of kidney cancer who have no other treatment options. It aims to find the safest dose and see if the drug can effectively fight the cancer.
Immunotherapy
Entinostat + Aldesleukin for Kidney Cancer
Recruiting1 awardPhase 1 & 2
Los Angeles, California
This trial is testing a combination of drugs to treat metastatic kidney cancer. Entinostat may stop tumor cell growth, and aldesleukin may stimulate white blood cells to kill cancer cells. The goal is to see if this combination is more effective than current treatments.
Trials for Metastatic Patients
Cyclin-Dependent Kinase Inhibitor
NKT2152 + Palbociclib + Sasanlimab for Kidney Cancer
Recruiting1 awardPhase 2
Omaha, Nebraska
This trial is testing a new drug combination for patients with advanced kidney cancer who have already tried other treatments. The goal is to see if these drugs can work better together to stop cancer growth and help the immune system fight the disease.
HIF2α Inhibitor
Oral NKT2152 for Kidney Cancer
Recruiting1 awardPhase 1 & 2
Scottsdale, Arizona
This trial is testing NKT2152, a new oral drug, in adults with a specific type of kidney cancer who have no other treatment options. It aims to find the safest dose and see if the drug can effectively fight the cancer.
Kinase Inhibitor
Savolitinib vs. Sunitinib for Kidney Cancer
Recruiting2 awardsPhase 3
La Jolla, California
This trial is for patients with a certain type of kidney cancer that has spread and cannot be removed by surgery. The goal is to see if a new medication, savolitinib, is better than the current standard of care, sunitinib, and to learn about any side effects.
Immunotherapy
Entinostat + Aldesleukin for Kidney Cancer
Recruiting1 awardPhase 1 & 2
Los Angeles, California
This trial is testing a combination of drugs to treat metastatic kidney cancer. Entinostat may stop tumor cell growth, and aldesleukin may stimulate white blood cells to kill cancer cells. The goal is to see if this combination is more effective than current treatments.
Phase 3 Trials
Kinase Inhibitor
Savolitinib vs. Sunitinib for Kidney Cancer
Recruiting2 awardsPhase 3
La Jolla, California
This trial is for patients with a certain type of kidney cancer that has spread and cannot be removed by surgery. The goal is to see if a new medication, savolitinib, is better than the current standard of care, sunitinib, and to learn about any side effects.
Pembrolizumab for Bladder Cancer
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial looks at how well pembrolizumab works in treating patients with muscle-invasive bladder cancer or locally advanced urothelial cancer. Monoclonal antibodies that block the PD-1 axis can interfere with the ability of tumor cells to grow.
Tyrosine Kinase Inhibitor
Pazopanib for Renal Cell Carcinoma
Recruiting1 awardPhase 3
Fairbanks, Alaska
This trial is testing whether pazopanib hydrochloride can help prevent the return of kidney cancer in patients who have had surgery to remove it. The medication aims to stop cancer cell growth and block blood flow to tumors. Patients will take the drug for several months and be monitored frequently. Pazopanib has been approved for treating kidney cancer since 2009.
Trials With No Placebo
Cyclin-Dependent Kinase Inhibitor
NKT2152 + Palbociclib + Sasanlimab for Kidney Cancer
Recruiting1 awardPhase 2
Omaha, Nebraska
This trial is testing a new drug combination for patients with advanced kidney cancer who have already tried other treatments. The goal is to see if these drugs can work better together to stop cancer growth and help the immune system fight the disease.
Cryoablation
Cryoablation-Assisted Surgery for Kidney Cancer
Recruiting1 award2 criteria
Miami Lakes, Florida
This trial will compare two methods of controlling blood loss during surgery for kidney cancer: renal cryoablation (freezing the tumor) and selective arterial renal ischemia (restricting blood flow to the kidney).
HIF2α Inhibitor
Oral NKT2152 for Kidney Cancer
Recruiting1 awardPhase 1 & 2
Scottsdale, Arizona
This trial is testing NKT2152, a new oral drug, in adults with a specific type of kidney cancer who have no other treatment options. It aims to find the safest dose and see if the drug can effectively fight the cancer.
Kinase Inhibitor
Savolitinib vs. Sunitinib for Kidney Cancer
Recruiting2 awardsPhase 3
La Jolla, California
This trial is for patients with a certain type of kidney cancer that has spread and cannot be removed by surgery. The goal is to see if a new medication, savolitinib, is better than the current standard of care, sunitinib, and to learn about any side effects.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.